摘要
目的探讨肺复方联合化疗对非小细胞肺癌(Non-Small-Cell Lung Cancer,NSCLC)患者预后及血清胰岛素样生长因子-Ⅱ(Insulin-like Growth FactorⅡ,IGF-Ⅱ)、降钙素原(Procalcitonin,PCT)水平的影响。方法选取2019年2月—2021年2月期间湖南省中医药研究院附属医院收治的100例NSCLC患者,抽签随机分为观察组与对照组,每组各50例。两组患者入院后均行化疗,对照组使用紫杉醇联合顺铂化疗,于每一疗程开始时第1天使用紫杉醇,剂量:135~170 mg/m^(2);于疗程开始1~3 d注射顺铂,剂量:75 mg/m^(2)。观察组在对照组基础上口服肺复方,制成250 ml/剂,1剂/d。4周为1个疗程,治疗2疗程后,观察比较两组患者临床疗效、不良反应发生率及随访1年后的生存情况,治疗前后肿瘤因子水平[血管内皮生长因子(Vascular Endothelial Growth Factor,VEGF)、癌胚抗原(Carcinoembryonic antigen,CEA)、低氧诱导因子(Hypoxia Inducible Factor-1,HIF-1α)]及血清胰岛素样生长因子-Ⅰ(Insulin-like Growth FactorⅠ,IGF-Ⅰ)、血清胰岛素样生长因子-Ⅱ(Insulin-like Growth FactorⅡ,IGF-Ⅱ)、降钙素原(Procalcitonin,PCT)水平。采取Kaplan-Meier法绘制NSCLC患者生存曲线。结果治疗后观察组患者总缓解率78.00%(39/50)明显高于对照组58.00%(29/50),差异有统计学意义(P<0.05)。治疗后两组患者VEGF、CEA、HIF-1α、IGF-Ⅰ、IGF-Ⅱ、PCT水平均较治疗前明显降低,差异有统计学意义(P<0.05);且观察组VEGF、CEA、HIF-1α、IGF-Ⅰ、IGF-Ⅱ、PCT水平明显低于对照组,差异有统计学意义(P<0.05)。治疗期间,两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。Kaplan-Meier生存分析显示观察组患者1年存活明显高于对照组,差异有统计学意义(Log-Rank=5.202,P=0.023)。结论肺复方联合化疗治疗NSCLC疗效较好,可有效改善肿瘤因子水平,降低IGF-Ⅰ、IGF-Ⅱ、PCT表达,且1年存活率较高,有应用价值。
Objective To observe the effects of Lung Compound combined with chemotherapy on the prognosis and serum levels of insulin-like growth factor-Ⅱ(IGF-Ⅱ)and procalcitonin(PCT)in the patients with non-small cell lung cancer(NSCLC).Methods A total of 100 NSCLC patients admitted the Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine from February 2019 to February 2021 were included in this study and randomly assigned into an observation group(n=50)and a control group(n=50)by drawing lots.Both groups received chemotherapy(paclitaxel combined with cisplatin)after admission.Paclitaxel was applied on the first day of each course of treatment,with the dose of 135~170 mg/m^(2).Cisplatin was injected at a dose of 75 mg/m^(2) 1~3 days from the beginning of the treatment course.The observation group was orally administrated with Lung Compound(250 ml/dose,1 dose/day)on the basis of the therapy in the control group.Each course of treatment lasted for 4 weeks,and both groups were treated for 2 courses.The clinicalefficacy,incidence of adverse reactions,and survival within 1 year of follow-up were compared between the two groups.The levels of tumor factors[vascular endothelial growth factor(VEGF),carcino-embryonic antigen(CEA),and hypoxia-inducible factor-1α(HIF-1α)]and the serum levels of insulin-like growth factor-I(IGF-Ⅰ),IGF-Ⅱ,and PCT were compared between before and after treatment as well as between the two groups.Kaplan-Meier method was employed to plot the survival curve of NSCLC patients.Results The total remission rate in the observation group was 78.00%(39/50),which was higher than that(58.00%,29/50)in the control group(P<0.05).The levels of VEGF,CEA,HIF-1α,IGF-Ⅰ,IGF-Ⅱ,and PCT after treatment declined compared with those before treatment(P<0.05)and were lower in the observation group than in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The Kaplan-Meier survival analysis showed that the 1-year survival of patients in the observation group was higher than that in the control group(Log-rank=5.202,P=0.023).Conclusion Lung Compound combined with chemotherapy has good efficacy in the treatment of NSCLC,which can effectively restore the levels of tumor factors,down-regulate the expression of IGF-Ⅰ,IGF-Ⅱ,and PCT,and improve the 1-year survival,demonstrating a promising application value.
作者
罗星
陈琪
胡羽萌
LUO Xing;CHEN Qi;HU Yu-meng(Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine,Changsha Hunan 410000;Changsha Central Hospital Affiliated to University of South China,Changsha Hunan 410000)
出处
《世界中西医结合杂志》
2022年第11期2241-2244,2249,共5页
World Journal of Integrated Traditional and Western Medicine
基金
国家中医药管理局第六批全国老中医药专家学术经验继承项目(2017-29)。
作者简介
通信作者:胡羽萌,Email:huyumeng1229@163.com。
